Marker Therapeutics
MRKR
32 hedge funds and large institutions have $5.04M invested in Marker Therapeutics in 2025 Q1 according to their latest regulatory filings, with 3 funds opening new positions, 10 increasing their positions, 6 reducing their positions, and 3 closing their positions.
67% more repeat investments, than reductions
Existing positions increased: 10 | Existing positions reduced: 6
0% more first-time investments, than exits
New positions opened: 3 | Existing positions closed: 3
3% less funds holding
Funds holding: 33 → 32 (-1)
3.51% less ownership
Funds ownership: 41.77% → 38.26% (-3.5%)
90% less capital invested
Capital invested by funds: $49.5M → $5.04M (-$44.4M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Hudson Bay Capital Management
Stamford,
Connecticut
|
+$308K |
| 2 |
Renaissance Technologies
New York
|
+$79.6K |
| 3 |
Squarepoint
New York
|
+$79.3K |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$59K |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$56.8K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Alyeska Investment Group
Chicago,
Illinois
|
-$1.2M |
| 2 |
Northern Trust
Chicago,
Illinois
|
-$79.3K |
| 3 |
EGM
Engineers Gate Manager
New York
|
-$51.1K |
| 4 |
Millennium Management
New York
|
-$50.1K |
| 5 |
LPL Financial
San Diego,
California
|
-$11.9K |
MRKR Hedge Fund Activity: Q1 2025 in Review
32 of the 7,476 institutional investors tracked by Wall St. Rank reported a position in Marker Therapeutics (MRKR) for Q1 2025, worth a combined $5.04M — down 90% from $49.5M a quarter earlier.
Fund positioning in MRKR was balanced in Q1 2025: 3 funds opened new positions, 3 closed out, 10 added to existing stakes and 6 trimmed.
The largest buyer was Hudson Bay Capital Management, adding an estimated $308K. The largest seller was Alyeska Investment Group, cutting an estimated $1.2M.
- 32 institutional investors held Marker Therapeutics (MRKR) as of Q1 2025, down from 33 in Q4 2024.
- Funds reported $5.04M of Marker Therapeutics stock for Q1 2025, down 90% quarter-over-quarter.
- 3 funds opened new Marker Therapeutics positions in Q1 2025 and 3 closed out, a net change of 0 holders.
- The largest Marker Therapeutics buyer in Q1 2025 was Hudson Bay Capital Management, an estimated $308K added.
- The largest Marker Therapeutics seller in Q1 2025 was Alyeska Investment Group, an estimated $1.2M sold.
Based on aggregated 13F filings for Q1 2025.